［1］Tan CS,Cho BC,Soo RA.Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer［J］.Lung Cancer,2016,93:59-68.
［2］ Zhou C.Lung cancer molecular epidemiology in China:Recent trends［J］.Transl Lung Cancer Res,2014,3(5):270-279.
［3］Alexopoulos EC,Malli F,Mitsiki E,et al.Frequency and risk factors of COPD exacerbations and hospitalizations:A nationwide study in Greece(Greek obstructive lung disease epidemiology and health economics:Golden study)［J］.Int J Chron Obstruct Pulmon Dis,2015,10:2665-2674.
［4］Lamprecht B,Soriano JB,Studnicka M,et al.Determinants of under diagnosis of COPD in national and international surveys［J］.Chest,2015,148(4):971-985.
［5］Skillrud DM,Offord KP,Miller RD.Higher risk of lung cancer in chronic obstructive pulmonary disease.A prospective,matched,controlled study［J］.Ann Intern Med,1986,105(4):503-507.
［6］Schiavon M,Marulli G,Nannini N,et al.COPD-related adenocarcinoma presents low aggressiveness morphological and molecular features compared to smoker tumors［J］.Lung Cancer,2014,86(3):311-317.
［7］Lowry KP,Gazelle GS,Gilmore ME,et al.Personalizing annual lung cancer screening for patients with chronic obstructive pulmonary disease:A decision analysis［J］.Cancer,2015,121(10):1556-1562.
［8］Vermaelen K,Brusselle G.Exposing a deadly alliance:Novel insights into the biological links between COPD and lung cancer［J］.Pulm Pharmacol Ther,2013,26(5):544-554.
［9］Anthonisen NR,Skeans MA,Wise RA,et al.The effects of a smoking cessation intervention on 14.5-year mortality:A randomized clinical trial［J］.Ann Intern Med,2005,142(4):233-239.
［10］Rooney C,Sethi T.The epithelial cell and lung cancer:The link between chronic obstructive pulmonary disease and lung cancer［J］.Respiration,2011,81(2):89-104.
［11］Powell HA,Iyen-Omofoman B,Baldwin DR,et al.Chronic obstructive pulmonary disease and risk of lung cancer:The importance of smoking and timing of diagnosis［J］.J Thorac Oncol,2013,8(4):e34-e35.
［12］Young RP,Duan F,Chiles C,et al.Air flow limitation and histology shift in the national lung screening trial.the NLST-ACRIN cohort substudy［J］.Am J Respir Crit Care Med,2015,192(9):1060-1067.
［13］De Torres JP,Marín JM,Casanova C,et al.Lung cancer in patients with chronic obstructive pulmonary disease- incidence and predicting factors［J］.Am J Respir Crit Care Med,2011,184(8):913-919.
［14］Lee SJ,Lee J,Park YS,et al.Impact of chronic obstructive pulmonary disease on the mortality of patients with non-small-cell lung cancer［J］.J Thorac Oncol,2014,9(6):812-817.
［15］Kranenburg AR,Willems-Widyastuti A,Mooi WJ,et al.Chronic obstructive pulmonary disease is associated with enhanced bronchial expression of FGF-1,FGF-2,and FGFR-1［J］.J Pathol,2005,206(1):28-38.
［16］Weiss J,Sos ML,Seidel D,et al.Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer［J］.Sci Transl Med,2010,2(62):62-93.
［17］Wu YM,Su F,Kalyana-Sundaram S,et al.Identification of targetable FGFR gene fusions in diverse cancers［J］.Cancer Discov,2013,3(6):636-647.
［18］Shi L,Xin Q,Chai R,et al.Ectopic expressed miR-203 contributes to chronic obstructive pulmonary disease via targeting TAK1 and PIK3CA［J］.Int J Clin Exp Pathol,2015,8(9):10662-10670.
［19］McGowan M,Hoven AS,Lund-Iversen M,et al.PIK3CA mutations as prognostic factor in squamous cell lung carcinoma［J］.Lung Cancer,2017,103:52-57.
［20］Song Z,Yu X,Zhang Y.Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma［J］.Cancer Med,2016,5(10):2694-2700.
［21］Wu SG,Chang YL,Yu CJ,et al.The role of PIK3CA mutations among lung adenocarcinoma patients with primary and acquired resistance to EGFR tyrosine kinase inhibition［J］.Sci Rep,2016,6:35249
［22］Shaykhiev R,Otaki F,Bonsu P,et al.Cigarette smoking reprograms apical junctional complex molecular architecture in the human airway epithelium in vivo［J］.Cell Mol Life Sci,2011,68(5):877-892.
［23］Li G,Zhao J,Peng X,et al.The mechanism involved in the loss of PTEN expression in NSCLC tumor cells［J］.Biochem Biophys Res Commun,2012,418(3):547-552.
［24］Li H,Zhang P,Sun X,et al.MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-resistant lung adenocarcinoma cells［J］.Int J Oncol,2015,47(4):1379-1392.
［25］Bozinovski S,Vlahos R,Anthony D,et al.COPD and squamous cell lung cancer:Aberrant inflammation and immunity is the common link［J］.Br J Pharmacol,2016,173(4):635-648.
［26］Mahmood MQ,Sohal SS,Shukla SD,et al.Epithelial mesenchymal transition in smokers:Large versus small airways and relation to airflow obstruction［J］.Int J Chron Obstruct Pulmon Dis,2015,10:1515-1524.
［27］Palmisano WA,Divine KK,Saccomanno G,et al.Predicting lung cancer by detecting aberrant promoter methylation in sputum［J］.Cancer Res,2000,60:5954-5958.
［28］Brock MV,Hooker CM,Ota-Machida E,et al.DNA methylation markers and early recurrence in stage I lung cancer［J］.N Engl J Med,2008,358:1118-1128.
［29］Lai JC,Wu JY,Cheng YW,et al.O6-Methylguanine-DNA methyltransferase hypermethylation modulated by 17beta-estradiol in lung cancer cells［J］.Anticancer Res,2009,29:2535-2540.
［30］Sato T,Arai E,Kohno T,et al.Epigenetic clustering of lung adenocarcinomas based on DNA methylation profiles in adjacent lung tissue:Its correlation with smoking history and chronic obstructive pulmonary disease［J］.Int J Cancer,2014,135(2):319-334.
［31］Zhang JY,Wang Y,Prakash C.Xenobioticmetabolizing enzymes in human lung［J］.Curr Drug Metab,2006,7:939-948.
［32］Caramori G,Adcock I.Gene-environment interactions in the development of chronic obstructive pulmonary disease［J］.Curr Opin Allergy Clin Immunol,2006,6:323-328.
［33］Kikuchi A,Yamaya M,Suzuki S,et al.Association of susceptibility to the development of lung adenocarcinoma with the heme oxygenase-1 gene promoter polymorphism［J］.Hum Genet,2005,116:354-360.
［34］Fu WP,Sun C,Dai LM,et al.Relationship between COPD and polymorphisms of HOX-1 and mEPH in a Chinese population［J］.Oncol Rep,2007,17:483-488.
［35］Ben-Zaken CS,Pare PD,Man SF,et al.The growing burden of chronic obstructive pulmonary disease and lung cancer in women:Examining sex differences in cigarette smoke metabolism［J］.Am J Respir Crit Care Med,2007,176:113-120.
［36］Sharma N,Singh A,Singh N,et al.Genetic polymorphisms in GSTM1,GSTT1 and GSTP1 genes and risk of lung cancer in a north Indian population［J］.Cancer Epidemiol,2015,39(6):947-955.
［37］Lakhdar R,Denden S,Knani J,et al.Combined analysis of EPHX1,GSTP1,GSTM1 and GSTT1 gene polymorphisms in relation to chronic obstructive pulmonary disease risk and lung function impairment［J］.Dis Markers,2011,30(5):253-263.
［38］Chen SJ,Huang SS,Chang NS.Role of WWOX and NF-κB in lung cancer progression［J］.Transl Respir Med,2013,1(1):15.
［39］Schuliga M.NF-kappaB signaling in chronic inflammatory airway disease［J］.Biomolecules,2015,5(3):1266-1283.
［40］Shibata T,Ohta T,Tong KI,et al.Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy［J］.Proc Natl Acad Sci USA,2008,105:13568-13573.
［41］Ohta T,Iijima K,Miyamoto M,et al.Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth［J］.Cancer Res,2008,68:1303-1309.
［42］Bocci V,Valacchi G.Nrf2 activation as target to implement therapeutic treatments［J］.Front Chem,2015,3:4.
［43］Beane J,Sebastiani P,Liu G,et al.Reversible and permanent effects of tobacco smoke exposure on airway epithelial gene expression［J］.Genome Biol,2007,8:R201.
［44］Steiling K,Kadar AY,Bergerat A,et al.Comparison of proteomic and transcriptomic profiles in the bronchial airway epithelium of current and never smokers［J］.Plos One,2009,4:e5043.
［45］Huang L,He R,Luo W,et al.Aldo-Keto reductase family 1 member B10 inhibitors:Potential drugs for cancer treatment［J］.Recent Pat Anticancer Drug Discov,2016,11(2):184-196.
［46］Sancar A,Lindsey-Boltz LA,Unsal-Kacmaz K,et al.Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints［J］.Annu Rev Biochem,2004,73:39-85.
［47］Wei Q,Cheng L,Amos CI,et al.Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk:A molecular epidemiologic study［J］.J Natl Cancer Inst,2000,92:1764-1772.
［48］Pfeifer GP.How the environment shapes cancer genomes［J］.Curr Opin Oncol,2015,27(1):71-77.
［49］Lundin A,Driscoll B.Lung cancer stem cells:Progress and prospects［J］.Cancer Lett,2013,338(1):89-93.
［50］Regala RP,Davis RK,Kunz A,et al.Atypical protein kinase C{iota} is required for bronchioalveolar stem cell expansion and lung tumorigenesis［J］.Cancer Res,2009,69(19):7603-7611.
［51］Deja S,Porebska I,Kowal A,et al.Metabolomics provide new insights on lung cancer staging and discrimination from chronic obstructive pulmonary disease［J］.J Pharm Biomed Anal,2014,100:369-380.
［52］Peng H,Yang M,Chen ZY,et al.Expression and methylation of mitochondrial transcription factor a in chronic obstructive pulmonary disease patients with lung cancer［J］.Plos One,2013,8(12):e82739.
［53］Boelens MC,Gustafson AM,Postma DS,et al.A chronic obstructive pulmonary disease related signature in squamous cell lung cancer［J］.Lung Cancer,2011,72(2):177-183.
［54］Guan P,Yin Z,Li X,et al.Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues［J］.J Exp Clin Cancer Res,2012,31:54.
［55］Vsa U,Vooder T,Kolde R,et al.Meta-analysis of microRNA expression in lung cancer［J］.Int J Cancer,2013,132(12):2884-2893.
［56］Yu L,Todd NW,Xing L,et al.Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers［J］.Int J Cancer,2010,127(12):2870-2878.
［57］Xing L,Todd NW,Yu L,et al.Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers［J］.Mod Pathol,2010,23(8):1157-1164.
［58］Kara M,Kirkil G,Kalemci S.Differential expression of MicroRNAs in chronic obstructive pulmonary disease［J］.Adv Clin Exp Med,2016,25(1):21-26.
［59］De-Torres JP,Casanova C,Marín JM,et al.Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients:A pilot study［J］.Respir Med,2013,107(5):702-707.
［60］Wille MM,Dirksen A,Ashraf H,et al.Results of the randomized danish lung cancer screening trial with focus on high-risk profiling［J］.Am J Respir Crit Care Med,2016,193(5):542-551.
［61］Woodruff PG,Wolff M,Hohlfeld JMK,et al.Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor(BIBW 2948 BS) in chronic obstructive pulmonary disease［J］.Am J Respir Crit Care Med,2010,181:438-445.
［62］Zhao Q,Gu X,Zhang C,et al.Blocking M2 muscarinic receptor signaling inhibits tumor growth and reverses epithelial-mesenchymal transition(EMT) in non-small cell lung cancer(NSCLC)［J］.Cancer Biol Ther,2015,16(4):634-643.
［63］Spindel ER.Cholinergic targets in lung cancer［J］.Curr Pharm Des,2016,22(14):2152-2159.
［64］Tashkin DP,Celli B,Senn S,et al.A 4-year trial of tiotropium in chronic obstructive pulmonary disease［J］.N Engl J Med,2008,359(15):1543-1554.
［65］Liu R,Xu KP,Tan GS.Cyclooxygenase-2 inhibitors in lung cancer treatment:Bench to bed［J］.Eur J Pharmacol,2015,769:127-133.